New Clinical Interpretation Capabilities Leading to New Product Launches

  • Rainbow Genomics constantly develops new genetic analysis technologies and their clinical applications

  • By working with our clinical partners and their platforms, we developed the following new products and genetic analysis technologies

Pediatric Exome Health Screening Test Product Development

  • For the Pediatric Exome Health Screening Test, which is based on the BabySeq project implemented at the Boston Children’s Hospital and Harvard Medical School, we co-developed an additional gene panel of approximately 200 genes with Fabric Genomics and clinical specialists in Asia.

  • The panel includes the latest genes annotated (2018) for childhood-onset disorders. Our total interpretation menu now includes over 1600 genes associated with over 1000 childhood-onset genetic disorders.

Cardio Panel for Focused Heart Disease Analysis Coupled with Whole Exome Clinical Interpretation

  • By working with the team at UCLA’s Clinical Genomic Center, Rainbow co-developed a cardio panel with over 100 genes that target monogenic cardiovascular diseases and muscular dystrophy disorders.

  • This panel is now available for order with Rainbow’s adult and pediatric whole exome sequencing test, enabling their medical team to focus on a range of cardiovascular disorders while interpreting patient’s other symptoms.

Cancer Gene Panel for Comprehensive Cancer Screening Coupled with Baylor’s Exome Clinical Interpretation

Integrated Common Cancer Risk Assessment to Motivate Improved Liefstyle

  • Working with Baylor Genetics’ clinical team, Rainbow co-developed over 100 genes for screening of most known hereditary cancer gene variants. This is the most comprehensive cancer screening test available to individuals without symptoms or family history.

  • Rainbow also adopts the use of SNP (Single Nucleotide Polymorphism) markers for risk assessment of seven common cancers. We are among the first to provide both hereditary cancer risk (5-20 times higher risk compared to non-carriers) and common cancer risk (1.3-3 times higher risk compared to non-carriers) to motivate individuals to improve their life style/follow screening guidelines.